Genetic Technologies Interview to Air on Bloomberg International on the RedChip Money Report
MELBOURNE, Australia, May 17, 2019 (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) is pleased to announce an interview with its Chairman and CEO, Paul Kasian, will air on The RedChip Money Report television program. The interview will air Sunday, May 19, on Bloomberg International, available in 149 million homes across Europe, the Middle East, and Africa. Check local listings for times in your area.
In the exclusive interview, Kasian discusses Genetic Technologies’ recent developments, including the launch of its risk assessment tests for non-hereditary and hereditary breast cancer and colorectal cancer, as well as insight into the company’s robust development pipeline of innovative tests.
To view the interview segment, please visit: https://www.redchip.com/media/2114/
“The RedChip Money Report" delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies.
About Genetic Technologies Limited
Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. GTG offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company’s lead product, BREVAGenplus®, is a clinically validated risk assessment test for non-hereditary breast cancer and is first in its class. For more information, please visit www.brevagenplus.com and www.phenogensciences.com.
Genetic Technologies is developing a pipeline of risk assessment products including a novel colorectal cancer (CRC) test. For more information, please visit www.gtgcorporate.com
Safe Harbor Statement
Any statements in this press release that relate to the Company's expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with Genetic Technologies' business can be found in its periodic filings with the SEC.